CYBER-INTELLIGENCE-HOUSE
19.11.2021 09:02:09 CET | Business Wire | Press release
Hoxhunt, a premium enterprise cybersecurity awareness training platform, and Cyber Intelligence House, a leading provider of cyber intelligence, today announced a first-of-its-kind partnership designed to equip organizations with unprecedented protection from email attacks leveraging advanced insight across their dark-web-to employee-inbox lifecycle.
Hoxhunt’s CEO, Mika Aalto stated:
“This partnership with Cyber Intelligence House will open a whole new category of proactive cybersecurity awareness. Their industry-leading Cyber Exposure Platform adds a superior breadth and depth of intelligence from the Darkweb, Deep web and cyberspace forums and marketplaces to our dynamic awareness platform, typically 16 times more data than other solutions. By connecting threat intelligence with awareness, we can transform insight into foresight. Just imagine knowing an attack is likely coming and being able to train your employees with simulations of the actual phishing templates hackers purchased for their attack”.
Cyber Intelligence House’s CEO, Mikko Niemela adds:
“We are very excited to be partnering with Hoxhunt. Their best-in-class Cyber Awareness and Training platform allows organisations to adapt and defend against the ever rising volume of cyber threats that our platform identifies”.
About Hoxhunt:
Hoxhunt is a People-First Cybersecurity Platform that protects organizations and their employees from the risk of cyber attacks. Hoxhunt’s cognitive automation maps individually adaptive training curriculum to each employee’s skill level for optimal engagement. Hoxhunt empowers individuals with the tools and confidence to recognize and respond to attacks dynamically over time.
Hoxhunt enables security teams with real-time visibility into threats so they can react fast and limit their spread. The entire platform is autonomous, freeing up considerable time for security teams to focus on what matters.
To learn more about Hoxhunt, please visit https://www.hoxhunt.com or email info@hoxhunt.com .
About Cyber Intelligence House:
Cyber Intelligence House is a leading cyber intelligence company specialised in helping cyber security professionals and law enforcement to assess and monitor cyber exposure from the dark web, deep web, data breaches and online-assets. It is the trusted provider to government and law enforcement agencies globally, including Interpol and UNODC.
Cyber Intelligence House’s Cyber Exposure Platform (CEP) provides the world’s most comprehensive Cyber Threat database with over 10 years of data. 24/7 and collection and storing of new data at a rate of ~600 pages per second. CEP delivers unrivalled search and alerting performance with Deep scanning of over 250 metadata factors and machine learning enabled categorization of threats to provide deep insights into potential cyber threats.
To learn more about Cyber Intelligence House, please visit https://www.cyberintelligencehouse.com or email info@cyberintelligencehouse.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom